InspireMD reports zero major adverse events at 30 days in CGUARDIANS II TCAR study of CGuard Prime 80 cm stent

• InspireMD reported 30-day results from its CGUARDIANS II trial of the CGuard Prime 80 cm carotid stent for TCAR procedures.
• The 30-day readout is already presented, showing clean early safety with no major adverse clinical events reported.
• Findings also indicated strong short-term device performance, supporting use of the stent in high-risk patients undergoing TCAR.
• The company flagged a potential US approval in the second half of 2026, with an FDA PMA supplement currently under review.
• Management positioned the results as a step toward expanding into the TCAR market, cited at more than 35,000 US procedures annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110800PRIMZONEFULLFEED1001187002) on June 11, 2026, and is solely responsible for the information contained therein.